TL;DR
- Reimbursement has become unsustainably complex: What was once ingredient cost plus dispensing fee is now controlled by intermediaries using opaque practices.
- Pricing benchmarks are fundamentally flawed: Average Wholesale Price inflates costs 20-25% above reality, creating artificial starting points for reimbursement calculations nationwide.
- PBMs extract excessive profits through controversial methods: Spread pricing and DIR fees transfer wealth from pharmacies while creating financial unpredictability.
- Reform efforts show promise but need expansion: CMS 2024 rules and state legislation address some issues, though comprehensive solutions require broader implementation.
Table of Contents
Pharmacy reimbursements have become more complex and facing more challenges. And the structural issues affecting pharmacy compensation represent existential threats to patient access, especially in underserved communities.
These financial mechanisms directly impact both the business viability of pharmacies and the health outcomes of patients who depend on them.
Understanding the Pharmacy Reimbursement Fundamentals
- ingredient cost + professional dispensing fee = pharmacy reimbursement
The straightforward transaction is now a labyrinth that has pharmacies struggling to maintain financial viability. It’s become opaque with powerful intermediaries exercising unprecedented control over the financial flows between payers, pharmacies, and patients.
The Two Pillars of Reimbursement
Pharmacy compensation hinges on two components:
- Ingredient Cost
- what pharmacies pay to acquire prescription drugs from wholesalers or manufacturers
- It should, in theory, cover the actual cost of the medication itself
- Professional Dispensing Fee
- covers operational expenses, including pharmacist time, overhead, and the actual dispensing process
- represents the professional services of a pharmacy
But insufficient fees that fail to cover actual costs because of outdated benchmarks threaten a pharmacy’s viability. Imagine the rural pharmacy owner who is filling prescriptions at a loss just to keep serving their community.
I’ve spoken with countless pharmacy directors who feel trapped in a system that seems designed to minimize their compensation while maximizing profits for intermediaries. It’s a countdown to closure.
Problematic Pricing Benchmarks
One of the most controversial aspects of current pharmacy reimbursement models are the benchmarks used to determine ingredient costs.
Average Wholesale Price (AWP): The "Sticker Price" Problem
AWP has been the historical standard for determining ingredient cost in pharmacy contracts. And yet it’s earned the nickname “Ain’t What’s Paid” , because it doesn’t reflect the actual market transactions.
The formula typically looks like this:
- Reimbursement = (AWP – X%) + Dispensing Fee
X% represents a negotiated discount that varies widely between contracts. The fundamental problem? AWP is an inflated list price that doesn’t reflect true market conditions. This creates an artificial starting point for the entire reimbursement calculation.
Plus AWP isn’t calculated based on an average of wholesale prices at all. It’s a figure that’s been subject to manipulation. Investigations and litigation have revealed that AWP is artificially inflated by as much as 20-25% above actual transaction prices. This creates a system where the starting point for reimbursement calculations is fundamentally divorced from economic reality.
Moving Toward Acquisition Cost-Based Models
There’s been a push toward more transparent benchmarks based on actual acquisition costs because of the AWP controversy. Three new benchmarks aim to align reimbursement more closely with retail:
- National Average Drug Acquisition Cost (NADAC)
- based on monthly surveys of retail pharmacies’ invoice prices
- offers a more accurate reflection of what pharmacies actually pay for medications
- updated regularly and represents a significant improvement in transparency
- Actual Acquisition Cost (AAC)
- net cost pharmacies pay to acquire medications, including all discounts and adjustments
- gold standard for accuracy but can be challenging to determine consistently across different pharmacy settings
- Maximum Allowable Cost (MAC):
- upper limits set for reimbursing multi-source/generic drugs
- MAC lists can help control costs but they’re often proprietary to PBMs and lack transparency in how they’re determined and updated
Even as we move toward more transparent benchmarks I’ve observed the entities controlling the benchmarks often maintain information asymmetries that benefit their bottom line rather than ensuring fair compensation for pharmacies.
The PBM Factor: Middlemen with Outsized Influence
When I talk to healthcare executives about their pharmacy challenges, the conversation inevitably turns to pharmacy benefit managers (PBMs). These entities were originally created to process claims and negotiate drug prices. But they’ve evolved into market-making powerhouses with immense control over the pharmaceutical supply chain.
Market Concentration and Vertical Integration
The PBM market is highly concentrated, with the three largest firms controlling approximately 80% of prescription claims:
- Caremark (CVS Health)
- Express Scripts (Cigna)
- OptumRx (UnitedHealth Group)
What’s more concerning is the vertical integration we’re seeing. These PBMs now own or are affiliated with:
- major health insurers
- mail-order pharmacies
- specialty pharmacies
- retail pharmacy chains
This integration creates inherent conflicts of interest that can disadvantage independent pharmacies and limit patient choice. When a PBM owns its own pharmacy operations, it has a clear financial incentive to steer patients toward those affiliated entities, regardless of whether they offer the best value or service for patients.
Controversial Revenue Practices
PBMs employ two controversial mechanisms that impact pharmacy reimbursement:
- Spread Pricing
- PBM charges the health plan one price for a medication but reimburses the pharmacy a lower amount, pocketing the difference.
- Transfers wealth from both payers and providers to intermediaries.
- Lack of transparency allows spread pricing to flourish. Plan sponsors lack visibility into the reimbursement paid to pharmacies. It makes it impossible to know whether they’re receiving fair value for their pharmacy benefit dollars.
- The scale of this practice is staggering: a 2018 Ohio audit found that PBMs cost the state Medicaid program nearly $225 million through spread pricing.
- The Rebate Game
- PBMs negotiate substantial rebates from manufacturers in exchange for preferred formulary placement. Create perverse incentives to favor high-list-price drugs that generate larger rebates, even when lower-cost alternatives exist.
- Rebates often aren’t passed through to patients or plan sponsors in a transparent way.
- Patient cost-sharing is typically calculated based on the inflated list price, not the lower net price after rebates.
- Patients pay more out-of-pocket while intermediaries capture the savings from rebates.
- List prices for many medications continue to rise dramatically, even as net prices (after rebates) remain relatively stable.
The DIR Fee Crisis: A Threat to Pharmacy Viability
Perhaps the most acute threat to pharmacy sustainability today is the practice of Direct and Indirect Remuneration (DIR) fees. I’ve heard from countless pharmacy owners who describe these fees as existential threats to their businesses.
What Are DIR Fees?
DIR fees are retroactive “clawbacks” imposed by PBMs on pharmacies, often months after a prescription has been dispensed. These fees were created for Medicare Part D reconciliation purposes and have morphed into a major profit center for PBMs while creating financial unpredictability for pharmacies. This uncertainty makes it nearly impossible to manage cash flow effectively or make sound business decisions.
The impact has been dramatic:
- PBM margins on retail drugs increased from 23% to 31% between 2020 and 2022
- Pharmacy margins decreased from 7% to 3% during the same period
- DIR fees increased by an estimated $9.5 billion
A 2024 survey indicated that financial hardships could force over 30% of independent pharmacists out of business, this would be a devastating blow to healthcare access in vulnerable communities.
Regulatory Responses and Reform Efforts
The good news is that regulators and legislators have recognized these problems and are taking action. I’m encouraged by several developments:
The CMS 2024 DIR Rule
The Centers for Medicare & Medicaid Services (CMS) implemented a change effective January 1, 2024, requiring all pharmacy price concessions to be reflected at the point-of-sale rather than applied retroactively.
This change has two major benefits:
- reduces out-of-pocket costs for Medicare beneficiaries by ensuring that cost-sharing is calculated based on the final negotiated price
- provides pharmacies with financial predictability essential for business planning by eliminating retroactive clawbacks
This rule represents progress, but it’s important to note that it applies only to Medicare Part D. Commercial plans can still employ retroactive fee structures, highlighting the need for broader reform.
State-Level Reforms
States have become laboratories for PBM reform, with numerous legislatures enacting measures to:
- require MAC list transparency and timely updates
- ban spread pricing, particularly in Medicaid managed care
- mandate pass-through pricing models where PBM compensation is limited to administrative fees
- impose fiduciary duties on PBMs, requiring them to act in the best interests of their clients
The Supreme Court affirmed states’ rights to regulate PBM reimbursement practices in its ruling on Arkansas Act 900, which required PBMs to reimburse pharmacies at a price equal to or higher than the pharmacy’s wholesale cost. This decision opened the door for more aggressive state-level reforms aimed at protecting local pharmacies from below-cost reimbursement.
Value-Based Pharmacy Reimbursement
I see tremendous potential in value-based pharmacy reimbursement models that align payment with performance and patient outcomes. Two promising approaches are emerging:
These models link pharmacy compensation to specific performance measures, such as medication adherence or chronic disease management. They typically include:
- patient attribution mechanisms to identify which pharmacy is responsible for a patient’s care
- defined quality metrics that are clinically meaningful and within the pharmacy’s sphere of influence
- incentive structures that reward improved outcomes without creating undue financial risk
- documentation requirements for patient care services that demonstrate value beyond dispensing
2. Outcomes-Based Contracts (OBCs)
These arrangements link manufacturer payment to pre-specified patient outcomes. If a medication fails to achieve the promised results, the manufacturer provides a rebate or refund. This approach is particularly valuable for high-cost specialty medications where clinical efficacy is paramount.
Implementation Challenges and Critical Considerations
Value-based models hold promise and their successful implementation require addressing several critical barriers:
- Transparency
- performance measures and incentive structures must be clear and achievable
- pharmacies need to understand exactly what’s being measured and how they can influence those metrics
- Alignment
- financial incentives must truly reward value, not serve as veiled mechanisms for cost recoupment
- Data Infrastructure
- robust systems for tracking and analyzing outcomes are essential
- needs an investment in technology and processes to capture, share, and analyze relevant clinical data
- Pharmacy Engagement
- pharmacists must be involved in program design to ensure buy-in and feasibility
- performance measures may be unrealistic or fail to capture true value without pharmacists’ input
I’ve seen too many “performance-based” programs that pharmacists view as “rigged for failure” and “performance” programs that are simply traditional reimbursement with additional hurdles. True value-based models must create win-win scenarios that benefit patients, payers, and providers alike.
The Sustainable Path Forward for Pharmacy Rebates Reimbursements
As I work with hospitals and pharmacies to automate their patient philanthropy and free drug programs, I’m convinced that sustainable pharmacy reimbursement requires several fundamental shifts:
- Accurate Pricing Benchmarks
- move away from inflated list prices toward true acquisition cost metrics that reflect market reality, not arbitrary markups
- Adequate Dispensing Fees
- ensure fees cover the cost to dispense, which is significantly higher than what many contracts currently provide
- Transparent Models
- eliminate hidden fees and spread pricing in favor of clear, understandable compensation structures where all parties know exactly what’s being paid
- Value Alignment
- create incentives that reward quality and outcomes rather than volume alone to recognize the pharmacist’s role as a healthcare provider, not just a medication dispenser
- Regulatory Oversight
- maintain appropriate guardrails to prevent market abuses while allowing for innovation in payment models
When pharmacies close due to unsustainable reimbursement, patients lose access to essential medications and services. This is particularly devastating in rural and underserved areas where pharmacy alternatives may be limited or nonexistent.
We can create a more sustainable pharmacy ecosystem that serves patients, providers, and payers alike. The path forward requires collaboration, innovation, and a commitment to transparency.
